Does ticagrelor reduce the rate of stroke, myocardial infarction, or death at 90 days compared to aspirin in patients with acute ischemic stroke or transient ischemic attack?
In patients with acute ischemic stroke or transient ischemic attack, ticagrelor is not superior to aspirin for preventing the composite of stroke, myocardial infarction, or death at 90 days.
In our trial involving patients with acute ischemic stroke or transient ischemic attack, ticagrelor was not found to be superior to aspirin in reducing the rate of stroke, myocardial infarction, or death at 90 days. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01994720.).
Johnston et al. (Tue,) studied this question.